BOTHELL, WA and VANCOUVER, May 11 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that final survival data from a randomized Phase 2 trial evaluating OGX-011 in combination with docetaxel versus docetaxel alone as first-line chemotherapy in patients with metastatic castration-resistant prostate cancer will be featured in an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting. In addition, Phase 1 clinical data evaluating OncoGenex' second product candidate, OGX-427, will also be featured in an oral presentation at ASCO.
Abstracts will be made available to the public online on ASCO's website, www.ASCO.org, on Thursday, May 14 at 6:00 p.m. (EDT).
The oral presentations are scheduled for Saturday, May 30 at the ASCO meeting in Orlando, Florida. These formal presentations will also include new data that has been updated since abstracts were submitted to ASCO.
Abstract Presentation Information
Title: Mature results of a randomized phase II study of OGX-011 in combination with docetaxel/prednisone versus docetaxel/prednisone in patients with metastatic castration resistant prostate cancer Authors: K. N. Chi, S. J. Hotte, E. Yu, D. Tu, B. Eigl, I. Tannock, F. Saad, S. North, J. Powers, E. Eisenhauer, National Cancer Institute of Canada Clinical Trials Group Date: 4:30 p.m. - 4:45 p.m. EDT, Saturday, May 30, 2009 Location: Level 3, Chapin Theatre, W320, Orange County Convention Center Abstract: # 5012 Title: OGX-427, a 2'methoxyethyl antisense oligonucleotide (ASO), against HSP27: Results of a first-in-human trial Authors: S. J. Hotte, E. Y. Yu, H. W. Hirte, C. S. H
|SOURCE OncoGenex Pharmaceuticals, Inc.|
Copyright©2009 PR Newswire.
All rights reserved